Gilead, Teva acquitted in pay for delay generic HIV drugs case
Michael Vi

A California jury on Friday found that Gilead Sciences (NASDAQ:GILD) and Teva Pharmaceutical Industries (TEVA) did not engage in activities aimed at delaying generic versions of some of the former's HIV medicines.
In 2014, the two pharma signed a patent settlement. The jury found that it didn't violate any antitrust laws.

Gilead (GILD) was alleged to have paid Teva (TEVA) $1B to delay its generic version of Truvada (emtricitabine and tenofovir) and another HIV drug, Bloomberg Law reported.
Plaintiffs, who were seeking $3.6B, argued that Gilead (GILD) had a monopoly for HIV drugs by illicitly delaying generic competition for its medicines.

More on Gilead and Teva

Pfizer Or Gilead Sciences? Let's Ask Peter Lynch
Gilead Versus AbbVie: The Better Bet After Q1, 2023 Earnings
Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Teva Pharmaceutical Is Stabilizing Hinting A Payoff Potential